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Tumor angiogenesis factor (TAF) and its importance in determining a strategy
for cancer chemotherapy are discussed. It is suggested that inhibition of RNA
synthesis or increased RNA catabolism might interfere with the metabolism of
solid tumor cells more so than in normal cells, and thus hinder angiogenesis and
pursuant tumor growth by preventing the synthesis of the RNA component of
TAF. An attempt is made to indicate potential models for anti-angiogenesis agents
of this type. The drugs offered as initial prototypes for investigations along these
lines are actinomycin D (which likely has antimetabolite and anti-angiogenesis
activities), polyriboinosinic-polyribocytidylic acid (which likely has adjuvant and
anti-angiogenesis activities) and ribonuclease (which in theory might be a purely
anti-angiogenetic agent). It is noted that these models may turn out to be less
than ideal as therapeutic agents due to problems of toxicity, metabolism, potency,
or distribution, but nonetheless might serve to yield insights into the design of
new cancer chemotherapeutic drugs. In addition, some evidence is cited suggesting
that actinomycin D may be more effective against certain tumors when employed
in lower, chronic dosages rather than its present use in "loading" dosages.
The concept of anti-angiogenesis agents as fundamentally "tumoristatic" therapies
is discussed, and the likelihood that such agents might be effectively "tumoricidal"
in immunocompetent hosts is mentioned. The main promise of an anti-angiogenetic
strategy is efficacy against presently intractable slowly growing human cancers when
used in combination with other treatment modalities. In summary, a strategy of
cancer chemotherapy predicated upon interference with RNA synthesis or increase
in RNA catabolism is offered as a potential mechanism for establishing anti-angio-
genesis, and as a promising alternative and adjunct to present methods.
INTRODUCTION
This paper is an attempt to relate evidence from several disparate areas of inves-
tigation-from experiments designed to elucidate the mechanism of solid tumor
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neovascularization, and from investigations upon the ant,-tumor effects of the anti-
biotic actinomycin D (AcD), the synthetic polyribonucleotide polyriboinosinic-
polyribocytidylic acid (poly I:C) and the enzyme ribonuclease. The intent is to
suggest that recent findings support the possibility of relationships between the anti-
tumor activities of these agents and the substance "tumor angiogenesis factor
(TAF)" (1). If any of the hypothetical relationships obtain, they have significant
implications for evolving a strategy for cancer chemotherapy. It should be empha-
sized at the outset that the discussion, evaluation and proposals that follow are
highly speculative in nature, and should not be construed to be directly supported
by experimental data unless this is particularly specified. Some degree of circum-
stantiality of argument is due to the necessity of drawing upon studies that were
not designed to answer questions pertinent to the subject of this paper.
TUMOR ANGIOGENESIS FACTOR
Several years ago, Judah Folkman and his colleagues published their initial re-
port on the "Isolation of a Tumor Factor Responsible for Angiogenesis" (1).
Studies that support the existence of tumor angiogenesis factor (TAF) were later
contributed by a British group (2). As summarized in these and later reports, our
knowledge concerning how a tumor recruits and maintains its blood supply (neo-
vascularization) encompasses the following principles.
(1) Solid tumor growth requires neovascularization (1, 3, 4).
(2) In the absence of neovascularization, solid tumors cannot grow beyond
the size of a spheroid perhaps 2-3 mm in diameter (3).
(3) Neovascularization of solid tumors does not require direct cell to cell
contact between tumor cells and endothelial cells (1, 2).
The bioassay for TAF activity is somewhat inconvenient and requires large
amounts of test material (1). However, the possibility of more convenient in vitro
assays is being explored (6). TAF activity has been found in the cells of numerous
animal and human tumors, including Wilm's tumor and choriocarcinoma (1, 5).
The only normal tissues in which TAF activity has been found are human placentas
of 18 wk fetuses; regenerating normal tissue has been found to be TAF negative
(5). The experiments proving the existence of a specific angiogenetic factor were
well controlled against nonspecific inflammation and vascular proliferation (1).
Confirmation of neovascularization induced by TAF preparations has been by light
and electron microscopy (1, 7) and observation of radioactive nucleotide uptake
in mitotic endothelial cells (4, 8).
Preliminary characterization of TAF preparations has yielded the following
information.
(1) TAF isolated from tumor cell cytoplasm and nuclear nonhistone pro-
tein fractions contains varying amounts of associated ribonucleic acid
(RNA) and carbohydrate (1, 5, 9, 10).
(2) TAF has an estimated molecular weight of 100,000 daltons or less
(5, 9-12).
(3) TAF activity in the bioassay is destroyed by exposure to ribonuclease
and some proteases (1, 5, 10).
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Folkman and his colleagues interpret these data as implying that both the protein
and RNA components of TAF are essential to its biological activity. One possibility
is that the protein and/or carbohydrate components act as the transport and endo-
thelial cell receptor-specific moieties, much like a viral capsid, and that the RNA
specifies or initiates the proliferative response of the endothelial cell, much like
a viral genome. The sensitivity of TAF to ribonuclease suggests a crucial role for
the RNA component in any case.
It has also been discovered that withdrawal of TAF is followed by the disappear-
ance of newly formed capillaries (5, 9). This is especially relevant and hopeful
from the standpoint of potential therapeutic possibilities of "anti-angiogenesis." As
a possible mode of "anti-angiogenesis" (i.e., inhibition of the activity and effects
of TAF), Folkan's laboratory has attempted to generate antibodies against TAF.
Their lack of success at this time has been attributed to the seeming lack of species
specificity and the RNA content of TAF (5, 9). Human tumor TAF induces endo-
thelial cell mitoses in mice, rats, and rabbits (5).
An interesting question is how TAF is related to the only other cellular product
that has been found in all solid tumors examined. Unkeless et al. (13) demon-
strated that cells from animal and human solid tumors show increased fibrino-
lytic activity. A similar phenomenon has been reported by Yunis et al.
(14). This activity has not been thoroughly biochemically characterized, but ap-
parently it requires a cellular component and a serum component (13, 15). It
would be quite fortuitous and useful if the synthesis of TAF and the cellular fibrino-
lytic factor were genetically linked in their synthesis or regulation. Certainly it is
worth knowing if the protein component of TAF has any fibrinolytic activity.
The potential significance of TAF is best summarized by Folkman himself:
"Because endothelial cell turnover usually lags behind tumor cell growth, most solid tumors
may always be on the verge of necrosis. Interference with their capillary component
is likely to disturb this equilibrium and shift it toward more necrosis. If TAF is indeed
the mediator for neovascularization, then blockade of TAF might prevent vascularization,
i.e., anti-angiogenesis" (11).
Thus it is easy to see how anti-angiogenesis might become an important factor
in cancer therapy, especially as an adjunct to surgical tumor removal, and as
therapy for small, early growth tumors that have been detected, but not located.
This latter situation may become a very real problem as highly sensitive immuno-
logical or biochemical tumor detection methods are developed. The microscopic
tumor detected might be impossible to locate, but could be destroyed by a combina-
tion of anti-angiogenesis and other treatment modalities. Since small tumors seem
to be more susceptible to chemotherapy (11), anti-angiogenesis might be able to
potentiate the effects of our present therapeutic agents, and prevent development
of large metastases.
Folkman and his co-workers have emphasized preparation of anti-TAF anti-
bodies as a possible mechanism of anti-angiogenesis. However, as previously noted,
there is evidence that this may be very difficult, if not impossible. I would like
to suggest that an exploitable mechanism for anti-angiogenesis would be to inhibit
or interfere with the synthesis of, or to increase the catabolism of TAF, through
interference with the synthesis of, or increased degradation of its unusual RNA
component. Anti-angiogenetic agents that affect RNA metabolism might be ex-
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pected to have greater effects upon cells dependent upon TAF than on normal
cells. This possibility will be discussed in the ensuing sections of this paper.
ACTINOMYCIN D
It is worthy of note prior to this discussion of actinomycin D (AcD) that many
of the points made might, in most cases, apply to similar drugs which are now
coming into wider clinical use, such as adriamycin, and which possess similar, but
not identical properties. Actinomycin D is thought to exert its anti-tumor effects
by inhibiting the DNA-dependent synthesis of RNA (16-21). AcD is believed to
be selectively more toxic to certain tumor cells than to normal cells, because the
tumor cells replicate faster, and thus have a greater requirement for synthe-
sizing RNA. AcD forms a stable complex with cellular DNA,which prevents RNA
polymerase from transcribing the sequences at these sites (18, 21-23). The forma-
tion of the complex requires the presence of a guanine residue, preferably in the min-
or groove of the DNA helix. At concentrations ofAeD attainable in vivo, synthesis
of ribosomal RNA is preferentially suppressed. If slightly higher AcD concentra-
tions are attained, synthesis of all varieties of RNA is affected. In vitro, even higher
concentrations of the agent can directly interfere with cellular DNA synthesis (21).
It is interesting to note that the cytotoxicity ofAcD, seen primarily in proliferat-
ing cells, correlates better with tissue retention of the drug than with the degree
of acute inhibition of RNA synthesis (21, 22, 24). Schluederberg et al. (25)
and Benedetto and Djaczenko (26) have presented evidence that cells in culture
recover the ability to synthesize RNA in direct proportion to their ability to rid
their intracellular milieu ofAeD. It thus seems reasonable that, in the case of some
tumor cells in vivo, therapeutic success would depend upon maintaining suitable
intracellular AcD levels, and that intermittent AcD administration might have little
anti-tumor effect.
Given AcD's effects on RNA synthesis, and the unusual RNA content of TAF,
one might predict that AcDshould possess substantial anti-tumor activity against
malignancies dependent upon TAF for neovascularization. If local concentrations
of AcD high enough to inhibit TAF-RNA synthesis are attainable, selective toxicity
against recruitment of a blood supply by tumors might be achieved, i.e., anti-angio-
genesis. Not only would AcD inhibit tumor cell RNA synthesis in general, but
tumor expansion and survival would be mitigated against by the inhibition of TAF
synthesis. What evidence exists that AcD possesses unusual anti-tumor activity that
might be attributable to such a mechanism?
Firstly, AcD is perhaps the most potent known anti-neoplastic agent on a molar
basis (27). AcD inhibits by as much as 75% tumor induction by some chemical
carcinogens on mouse skin (28). Hela cell tumors injected into mice that are im-
munosuppressed remain localized and small with AeD treatment, rather than form-
ing large tumors as in untreated controls (29). AcD is the drug of choice for the
treatment of trophoblastic neoplasms (30-32). Probable cure rates approaching
80-100% are seen with AcD as the only therapy (31). This is quite the exception
in terms of efficacy for single agents employed against solid tumors. Promising re-
sponses to AcD by lung tumors (33), sarcomas (34), and testis cancer metastases
(35) have also been reported. AcD is the drug of choice in the treatment of Wilm's
tumor (36-38).
Despite this evidence, it is not possible to claim a wide-spectrum anti-tumor
activity for AcD compared with other drugs. However, the potential for wide-spec-
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trum activity may exist. The lack of evidence is at least partially a tribute to the
difficulties of screening any given drug against different tumors in vivo, and the
problems of determining dosage, scheduling and route of administration optima.
At present one can only state that in the cases where an effective regiment of AcD
therapy has been determined, its efficacy is rather impressive.
It has been argued that the main reason AcD and other antimetabolite drugs
are effective against certain tumors is that the tumors involved are extremely
quickly growing, and thus the differential drug toxicity between normal and tumor
cells is correspondingly great (i.e., tumor cells are more susceptible) (39). This
is certainly the major factor in the effectiveness of most "cell cycle active" antime-
tabolites, which depend on killing tumor cells for their success. AcD undoubtedly
functions in this manner too. Such "cell cycle active" agents are usually given inter-
mittently, in loading doses, until toxicity appears. However, if AcD can inhibit
TAF-RNA synthesis, there is reason to believe that its greatest effectiveness as
an anti-angiogenesis agent would be in prolonged, continual dosage at a level suffi-
cient to establish anti-angiogenesis. Its main effect in this case would be "tumoris-
tatic" rather than "tumoricidal." This would presumably be relevant even in quickly
growing tumors, because they are greatly dependent upon neovascularization for
their growth. Thus, in the case of Wilm's tumor and choriocarcinoma, AcD may
exert both cell killing and anti-angiogenetic effects. It is in the majority of human
tumors, which are, if anything, more slowly growing than normal cells, and thus
generally insusceptible to known antimetabolite cell killing agents, that anti-angio-
genesis may prove to be of critical importance. If an anti-angiogenesis agent were
administered continually, a tumor would not be able to grow further, and might
be expected to regress if the host were immunologically competent or if other thera-
pies were jointly employed.
At this point it is important to note that it is possible that a potent anti-angiogen-
esis agent might appear to be ineffective against tumors in the type of screening
systems now in use (39). This might be due to impaired immunological defences
of the host animal, incapable of eradicating residual tumor cells, or to the lack
of some form of adjunct therapy to destroy the bulk of any initial tumor load.
An anti-angiogenetic agent would exert primarily a "tumoristatic" effect, and only
be "tumoricidal" if the tumor were highly dependent upon vascularization. Even
then, in the immunologically incompetent host, a residual tumor of 2-3 mm in
diameter would surely remain, unable to grow, but also insensitive to any further
tumoricidal effects of the anti-angiogenesis drug. Thus, even if potent anti-angiogen-
esis agents are developed, immunotherapy and other "tumoricidal" treatment
modalities will be of utmost importance.
Admittedly, much of the foregoing is speculative, or at least inferential. There
is some evidence that AcD is effective at lower continual doses against more slowly
growing tumors. In mouse melanoma B16 (a known TAF producer), a relatively
slowly growing tumor, AcD may be most effective in prolonged, chronic usage
at doses lower than those heretofore thought optimal (21). Lower dosage, chronic
administration trials with AcD on slowly growing neoplasms in animals and humans
have not yet been reported to any significant extent. In view of the fact that the
'half-life of messenger RNA in cells is on the order of hours, to at most a few
days (40), it is not unreasonable to speculate that the "loading dose" scheme of
AcD administration may be poor strategy. This is especially so since it is known
that tumor cells may recover from AcD inhibition quite quickly (25).
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POLY I:C
Interest in the synthetic, double-stranded RNA polyriboinosinic-polyribocytidylic
acid (poly I:C) as an antitumor agent arises from reports that the substance pos-
sesses activity against the growth of sexeral murine transplantable tumors, of both
viral and nonviral origin (22, 41-46). The data of Levy et al. (41) indicated that
the growth of a reticulum cell sarcoma, a lymphatic lymphoma, a fibrosarcoma
and a human adenovirus-12-induced tumor was inhibited by injections of poly I:C.
Leukemic malignancies were least sensitive and the reticulum cell sarcoma was
most sensitive to the drug's effects. In the case of the reticulum cell sarcoma and
adenovirus-induced tumors, initiation of treatment even after the malignancy had
grown to moderate size led to tumor regression, and some animals were free of
disease two months after therapy ceased. With the, adenovirus-induced tumors, the
initiation of poly I: C therapy yielded a very rapid "massive necrosis and sloughing"
of tumor tissue in four of 10 animals, and marked regression in the other six.
The authors mention the possibility that poly I: C may act upon blood vessels and
aiffect the tumor blood supply. However, although many of the pathological changes
attributed to poly I: C toxicity appear to be effects of the agent upon vascular endo-
thelium (42), there is no explanation for why it might affect tumor blood vessels
more than "normal" vasculature.
Data have also been published recording the apparent cure of malignant mela-
noma B16 in mice, employing post-transplanation treatment with poly I:C (44).
Results indicating inhibition of the growth of the murine adenocarcinoma DBA
in mice (45) and of two-stage skin carcinogenesis (46) by poly I:C therapy have
appeared. Apparently, poly I:C is an anti-tumor agent with a surprisingly low
degree of cytotoxcity (47). Assessment of the effects of poly I:C on viral and
chemical oncogenesis in vitro and in vivo have, however, yielded less clear cut
findings. Poly I C enhances viral and chemical oncogenesis in certain cases and
protects against it in others (22, 48-51). The general consensus is that the anti-
tumor properties of poly I: C are unrelated to its ability to induce interferon (48-
52).
It has been suggested that poly I:C's anti-tumor activity is attributable to its
known activation and stimulation of the host's immunological defence system (22,
43). However, over the last few years, it has been demonstrated that poly I: C's
anti-tumor activity is equivalent in both immunocompetent and thoroughly im-
munosuppressed animals (53-55). In addition, poly I:C has been discovered to
have a variable effect on humoral immunity in normal mice, and can suppress im-
munity in some animals (55). This might explain the variable results in attempting
to employ poly I:C against oncogenic viruses. In any case, it does not seem likely
that poly I:C's anti-tumor activity is due primarily to its effects as an adjuvant.
Levy and Riley have shown that poly I: C strongly suppresses in vivo RNA and
protein synthesis in several different murine tumors (56). RNA and protein synthe-
sis in normal tissues was inhibited or enhanced depending on the mouse strain
tested. The inhibitory effect of poly I: C on macromolecular metabolism was
greater in tumor than non-tumor tissues. Supporting evidence suggests direct cellu-
lar toxicity of some kind as the mechanism for the anti-tumor activity of poly I:C
(57-60).
It has been demonstrated that some tumors show greatly increased transfer RNA
methylase enzyme activity (61-64). These studies included viral-induced (62) and
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spontaneously arising tumors (63). Concurrently, investigations concerning the
mechanism of anti-tumor action of polyI:C have shown that this agent significantly
inhibits tumor cell ribonucleotide reductase (65) and RNA methylases (66). These
latter authors suggest that "preferential inhibition of RNA methylation may be
partially responsible for the anti-tumor activity of polyI: C (66)."
I would like to take this hypothesis (66) one step further. I propose that the
anti-tumor activity of poly I:C, and its unusual effects on tumor vasculature are
due in part to interference with the synthesis of the RNA component of TAF.
Thus, poly I:C may be a potential anti-angiogenesis and "tumoristatic" agent, and
is worthy of investigation as such. This is particularly so, as it appears to have
low toxicity in preliminary human trials (67).
It is of interest to note, that of the two anti-angiogenesis agents thus far proposed,
one (AcD) is quite potent, but has yet to demonstrate the broad-spectrum activity
that would be expected, and the other, poly I:C, is less potent, but has been shown
to have effects upon a number of diverse tumors. The former compound acts at
the level of genetic transcription and the latter perhaps at the level of RNA "proces-
sing." Since these agents would exert their influences at different points in the same
metabolic pathway, it is to be expected that they would act synergistically. That
is, by inhibiting two different stages in the synthesis of TAF-RNA, they might,
used in combination, render tumor cells incapable of producing functional TAF.
Employing poly I:C in mice, Pieroni et al. (68) have found that simultaneous
administration of AcD increases the toxicity of poly I:C about 850-fold. Whether
this cooperative effect would also obtain in tumor tissues is unknown. However,
the possibility of employing lower, less toxic doses of AcD in combined chemo-
therapy with polyI: C is suggested by these findings.
RIBONUCLEASE
Since TAF by necessity functions extracellularly, it should be uniquely suscepti-
ble to chemotherapeutic or immunological attack. Difficulties in generating anti-
TAF antibodieshave been alluded to previously. However, TAF-RNA is sensitive
to ribonuclease; therefore, the possibility of exploiting this enzyme as an antiangio-
genesis agent is well worth considering. It has been known since the late 1950's
that ribonuclease administration can have an inhibitory effect on the growth of
ascites type tumor cells both in vivo and in vitro, and that the enzyme may enter
the cells involved (69). To the best of the author's knowledge, no studies concern-
ing administration of ribonuclease to humans as an antineoplastic agent have been
published. This is not surprising since there was no reason to even suspect this
enzyme might affect the growth of tumor tissue. Also, for reasons already discussed,
since ribonuclease could be expected to be an essentially pure "tumoristatic" agent,
in single agent trials, it very well might seem ineffective. However, a Russian group
has reported the inhibition of lymphosarcoma growth in rats by ribonuclease ther-
apy (70, English abstract). There is little other evidence for anti-tumor activity
on the part of ribonuclease employed as a single agent.
A most interesting study is that of Sartorelli (71). In this investigation the survi-
val of mice bearing sarcoma-I 80 ascites cell tumors was markedly enhanced by
AcD and ribonuclease conjoint therapy at levels of each compound, which, when
employed individually, displayed little or no effect. This series of experiments was
carefully controlled, and therapy began 24 hr post-tumor implantation. Given the
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RNA content of TAF, this cooperativity of tumor inhibition by agents interfering
with RNA metabolism takes on a promising light.
Certainly there is reason to hope that it may be possible to utilize ribonuclease
activity in vivo, particularly in the case of hepatomas. At least by histochemical
techniques, many tumor cells do not express ribonuclease activity (72). A recent
paper by Daoust is relevant (73). Briefly, he found that the development of preneo-
plastic liver nodules was focally accompanied by loss of ribonuclease activity. The
evidence appears convincing that a significant decrease in ribonuclease activity is
a prerequisite or concomitant event in the origin of chemically-induced hepatomas
in the rat (73-74).
It is interesting to consider whether host serum ribonuclease levels play any role
in the defence against or reaction to tumor growth. The data on serum alkaline
ribonuclease levels in patients having cancer is rather variable. However, a recent
study selected about 100 patients in good general health with a range
of histologic types of tumors, all of which were surgically resectable (75). The
observations were that the mean serum alkaline ribonuclease levels in patients with
adenocarcinomas and squamous carcinomas were significantly higher than those
of normal patients, or those with sarcomas or melanomas. The level of ribonuclease
was not related to whether or not metastatic spread had occurred. These results,
while far from conclusive, suggest that serum ribonuclease levels may possibly re-
flect the host's reaction to the presence of a growing tumor.
Certainly there is reason to hope that it may be possible to utilize ribonuclease
as a cancer chemotherapeutic agent, and that its postulated effects on TAF-RNA
might play an important role. If this potential usefulness of ribonuclease is realized,
the likelihood of its employment as a relatively nontoxic, selective, homologous
anti-tumor drug is a very real one. The technology for artificial synthesis of enzymes
of this type and size is now available due to the efforts of Merrifield and his col-
leagues (76).
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